Cognitive Effects of 500mg Trans-resveratrol

Not Applicable

Completed

• Conditions: Cognitive Performance; Mood
• Interventions: Dietary Supplement: Trans-resveratrol; Other: Placebo

• Registration Number: NCT01794351
• Lead Sponsor: Northumbria University

Brief Summary

This study investigated the potentially cognitive enhancing effects of 500mg trans-resveratrol in healthy, young humans.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Status Verified: 2013-02
• Study First Submitted: 2013-02-08
• Study First Submitted QC: 2013-02-15
• Last Update Submitted: 2013-02-15
• Study First Posted: 2013-02-18
• Last Update Posted: 2013-02-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• 18-35yrs, healthy.

Exclusion Criteria

• Drug/alcohol abuse, taking prescription medication (apart from contraception) or herbal supplements, having food intolerances or allergies, having suffered a head-injury or neurological/neuro-developmental disorder, uncorrected sight problems, pregnant or seeking to become so, excessive caffeine use (e.g. more than 6 cups of coffee per day).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo then resveratrol	Trans-resveratrol	Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
Placebo then resveratrol	Placebo	Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
Resveratrol then placebo	Trans-resveratrol	Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits
Resveratrol then placebo	Placebo	Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits

Primary Outcome Measures

Name	Time	Method
Number of participants with altered cognitive function at 40mins post-dose	40mins Post-dose	This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from the baseline to 40min post-dose scores.
Number of participants with altered cognitive function at 2.5hrs post-dose	2.5hrs post-dose	This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 2.5hr post-dose scores.
Number of participants with altered cognitive function at 4hrs post-dose	4hrs post-dose	This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 4hr post-dose scores.
Number of participants with altered cognitive function at 6hrs post-dose	6hrs post-dose	This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 6hr post-dose scores.

Secondary Outcome Measures

Name	Time	Method
Number of participants with altered mood at 40mins post-dose.	40mins post-dose	This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 40mins post-dose scores.
Number of participants with altered mood at 2.5hrs post-dose	2.5hrs post-dose	This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 2.5hrs post-dose scores.
Number of participants with altered mood at 4hrs post-dose	4hrs pos-dose	This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 4hrs post-dose scores.
Number of participants with altered mood at 6hrs post-dose	6hrs post-dose	This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 6hrs post-dose scores.

Trial Locations

Locations (1)

Brain performance and nutrition research centre, Northumbria university; 🇬🇧 Newcastle upon Tyne, Tyne and Wear, United Kingdom